AUTL — Autolus Therapeutics plc
Is AUTL overbought or oversold? Here is the current MarketMoodz read.
Autolus Therapeutics plc (AUTL) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $1.14. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.14
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Autolus Therapeutics plc (AUTL) is a clinical-stage cell therapy company whose value is driven by trial outcomes and execution of scale-up and funding plans. The company has technical expertise and a potentially differentiated pipeline, but limited near-term revenue and meaningful dilution risk if capital needs arise. Market preference for large-cap, defensive pharma and the general rotational tone reduce near-term investor appetite for mid/small-cap biotech idiosyncratic risk. Key near-term drivers are upcoming clinical readouts, partnership or licensing announcements, and financing activity; negative outcomes in any of these areas could compress the share price materially.
Key factors
- Clinical-stage cell therapy pipeline with potential high-value outcomes if late-stage data are positive
- High R&D and manufacturing expertise in CAR-T/autologous T-cell platforms that support differentiated product candidates
- Limited near-term commercial revenue; valuation driven primarily by trial readouts and milestone events
- Market context: investor preference for large-cap pharma and defensive names may reduce appetite for small-cap biotech risk
- Capital markets environment and recent sector activity increase the chance of dilution via equity or convertible financings
- Operational complexity and manufacturing scale-up requirements that could delay commercialization timelines
Risks
- Clinical trial setbacks or negative data that materially reduce addressable market or delay approvals
- Cash runway uncertainty leading to dilutive financing at unfavorable terms
- Regulatory challenges or slower-than-expected agency interactions
- Strong competition from larger, better-capitalized CAR-T and cell therapy developers
- Commercialization and manufacturing scale-up risk, including cost inflation and supply constraints
- Low trading liquidity and heightened volatility, amplifying downside on negative headlines
See today's live rating, score and targets
Members see the live hourly rating for AUTL — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.